Key result
Antifibrotic therapies targeting extracellular collagen show promise against post-MI LV remodeling and diastolic dysfunction.
Why the study?
Left ventricular remodeling after myocardial infarction involves extracellular collagen matrix remodeling, which plays a major role in LV dilation, dysfunction, and outcomes, but the impact of therapies targeting ECCM remains to be clarified.
Do therapies targeting the extracellular collagen matrix improve left ventricular remodeling after myocardial infarction?
Population
Survivors of myocardial infarction undergoing LV remodeling
Comparison
Therapies targeting extracellular collagen matrix (ACE-Is, aldosterone antagonists, ARBs)
Design
Review article
Authors
Loading...
Antifibrotic targeting of post-MI ECCM remodeling merits prospective trials; leaves open clinical efficacy and practice change.
Do therapies targeting the extracellular collagen matrix improve left ventricular remodeling after myocardial infarction?
This review emphasizes the critical role of the extracellular collagen matrix in post-MI ventricular remodeling and highlights the potential of antifibrotic therapies to mitigate LV dysfunction.
Bodh I. Jugdutt (2003) conducted a review in Myocardial infarction and ventricular remodeling. Antifibrotic therapies targeting extracellular collagen matrix was evaluated. Antifibrotic therapies targeting the extracellular collagen matrix represent a potential therapeutic approach for left ventricular remodeling and diastolic dysfunction after myocardial infarction.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: